The invention relates to the field of medicines, in particular to application of a bisindolylmaleimide derivative in preparation of a medicament for treating chronic granulocytic leukemia. The invention discloses the application of the bisindolylmaleimide derivative in preparation of the medicament for treating the chronic granulocytic leukemia. Compared with the prior art, the application has the advantages that the bisindolylmaleimide derivative activates a cancer suppressor gene p53 by inducing DNA damage, so that the cell period is stopped at the stage G2/M; the activity of topoisomerase is suppressed by suppressing an addictive dependent Raf-Erk passageway at the downstream of BCR-ABL, and the sensitivity of cells to the bisindolylmaleimide derivative is enhanced, so that the aim of treating BCR-ABL positive leukemia is fulfilled.